

Immune-mediated inflammatory diseases and nutrition: results from an online survey on patients' practices and perceptions

Thao Pham

Assistance Publique – Hôpitaux de Marseille, France

Harry Sokol

Assistance Publique -Hopitaux De Paris

Bruno Haliqua

Dermatologue

Graziella Pourcel

Fresenius Kabi (France)

Manuel Brun

Fresenius Kabi (France)

Emilie Pain (✉ emilie@carenity.com)

Carenity

Damien Testa

Carenity

Research Article

Keywords: Dietary behavior, Immune-mediated inflammatory diseases, Patient's Perception, Online Patient Community

Posted Date: January 21st, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-137887/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at BMC Nutrition on July 16th, 2021. See the published version at <https://doi.org/10.1186/s40795-021-00446-y>.

Abstract

Background The central role of microbiota and the contribution of diet in immune-mediated inflammatory diseases (IMID) are increasingly examined. However, patients' perspectives on nutrition and its impact on their disease has not received a lot of attention. We aimed to directly collect information from patients with IMID about their dietary behaviors and their perceptions of the influence of nutrition on their disease.

Methods Adult patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, Crohn's disease, ulcerative colitis or psoriasis registered in an online patient community were invited to participate in the study and complete an online self-administered questionnaire. We assessed patients' dietary knowledge and choices by collecting information on the diet regimens they were following or recommended and their perceptions of the diet and its consequences on their disease.

Results Fifty patients per target disease were included with a mean age of 48.1 years (95%CI 46.7–49.6). Other sociodemographic and clinical characteristics varied across the diseases. Since diagnosis, 44% of the patients changed their eating habits, mainly patients with inflammatory bowel disease with 69% of these making the change on their own initiative. Patients who did not change their diet habits reported not having received nutritional advice from their healthcare professionals (HCP) in 69% of the cases. The perceived impact of nutrition on their symptoms was mixed (overall 74% of the patients reported positive consequences and 60% negative ones) and varied across the diseases. Patients with psoriasis only experienced positive consequences from changing their diet, such as reduction of stress and improved mental health, while patients with Crohn's disease reported more negative effects such as increased fatigue and disturbed sleep. Patients with rheumatic diseases and ulcerative colitis reported weight loss and better physical fitness, but also increased fatigue.

Conclusions Even if differences exist across diseases, the importance of nutrition and its potential positive role in symptom management is acknowledged by the majority of the patients. However, there is a need and a demand from patients to receive more dietary advice. Developing therapeutic education tools on nutrition for people with IMID and involving patients' organizations would provide useful information and encourage communication between HCP and patients.

Background

Immune-mediated inflammatory diseases (IMID) cover a wide range of heterogeneous diseases which may affect one specific or multiple organs, tissues or systems [1]. Rheumatoid arthritis (RA), psoriasis (PsO), and chronic inflammatory bowel disease (IBD), which includes Crohn's disease (CD) and ulcerative colitis (UC), are among the most common IMID [2]. Common characteristic of IMID is their considerable impact on patient's physical, mental and social well-being and the quality of life of patients and their caregivers [3, 4]. This burden is substantial due to the chronic nature of IMID and because most of them are currently incurable and require life-long medical treatment. It has also been established that patients with an IMID are at higher risk for developing other IMIDs [5].

While the exact causes of immune system imbalance remain unknown, the coexistence of environmental and genetic factors are suspected to play an important role in the development of IMID. Exposure to environmental factors such as tobacco smoke and other chemicals, infectious agents, pharmaceutical agents, ultraviolet light or socioeconomic status is now commonly known to influence the development of IMID [6–9]. While clinicians' improved awareness of and diagnosis of IMID may have contributed to the higher global incidence rates of IMID, the significant increase over time paired with regional differences in incidence strongly suggest the influence of environmental factors [10, 11].

Recent evidence suggests that the gut microbiota plays a major role in immune function [12–15] and in IMID [14]. The bacterial composition of the gut microbiome is influenced by many factors including diet, hygiene and sanitary diseases, and smoking or stress [12, 15–17]. There is epidemiological evidence supporting the diet's role in influencing the gut microbiome with unbalanced gut microbiota composition associated to IMID [18–21].

There is a growing body of research on the contribution of diet in IMID. An association between dietary behavior and the risk of developing an IBD has been shown in several observational studies with an increased risk of CD observed with diet high in fat and meat while high fiber and fruit intakes were associated with decreased risk of CD [22, 23]. Several epidemiological studies suggest that polyunsaturated fatty acids may have a positive effect on RA development or the course of multiple sclerosis through their anti-inflammatory and antioxidant properties [24, 25]. In this context, even if nutritional care appears promising in controlling inflammation in IMID, current nutritional advice in the management of IMID is extremely diverse and varies according to the type of disease [13]. Dietary interventions in IMID management are rarely based on solid scientific background and every disease is not uniformly studied. While some dietary guidelines for IBD are available, less information is available for RA or PsO [26–28]. Enteral nutrition has however demonstrated a positive effect in CD, especially in pediatrics, on controlling disease activity and maintaining remission [29]. Its potent anti-inflammatory effect is well-established and international medical societies recommend enteral nutrition in their guidelines for clinical management of IBD [30, 31]. Moreover, long-term restrictive diets may be harmful to the patient, leading to deficiencies and other clinical consequences, thus the careful monitoring and assessment by healthcare professionals (HCP) including nutritional specialists is advised [15].

While numerous publications highlight the central role of microbiota and the possible impact of some types of diets on some IMID, few studies have evaluated patients' perception on nutrition and its impact on their disease. As patients' active involvement in treatment, in general, and dietary therapy, in particular, are key factors for success, we conducted a study to assess patients' knowledge of and behaviors toward diet and their perceptions of the influence of nutrition and diet on their rheumatologic, gastro-intestinal or dermatologic IMID disease.

Methods

Study design and participants

We conducted a cross-sectional study through the French Carenity platform (<https://www.carenity.com/>). Created in 2011, Carenity is an online patient community in which both patients living with a chronic disease and their caregivers can share their experiences, support each other and receive health information. The community also contributes to enhanced medical knowledge by generating real-world patient insights through online surveys which subscribers regularly voluntarily participate in without receiving payment. As of April 2019, when this research project was conducted, more than 500,000 patients and caregivers from six countries (France, Italy, Germany, Spain, United Kingdom and United States of America) were registered in the Carenity platform. In the current study, only patients aged 18 years and older, registered in the Carenity platform, living in France, had self-reported RA, ankylosing spondylitis (AS), psoriatic arthritis (PsA), CD, UC or PsO and consented to participate were eligible to take part in the study and fill out an online self-administered questionnaire.

Data collected

A specific self-administered questionnaire was designed for this study to be administered electronically to all patients. It consisted of 36 mandatory questions, 32 closed and 4 open (impact on daily life and way to help managing the impact, source of nutritional advice, expectations in terms of nutrition-related support). The same questionnaire was administered to all patients. However, questions related to complications were tailored to each category of diseases. Before finalization, the questionnaire was reviewed by three medical experts specialized in each of the disease groups (BH, TP, HS). Additionally, a patient from the French Carenity platform with RA reviewed it to assess its clarity and suitability.

Data were collected in a pseudonymous way over a one-month period.

Sociodemographic and clinical variables

Sociodemographic variables (age, gender, and socio-professional category using the French Classification of Professions and Socioprofessional Categories from the National Institute of Statistics and Economic Studies (INSEE)) along with height and weight were recorded and body mass index (BMI) was calculated. Disease duration was defined as the time between IMID diagnosis and inclusion in the study. Age at diagnosis, comorbidities, HCP in charge of follow-up, care facilities visited, complications and previous and current treatments were collected. Patients perceptions of their level of control over their disease was determined through an 11-item scale (0 = not at all controlled; 10 = perfectly controlled).

Dietary assessment

Dietary behavior was assessed by collecting information on which dietary care regimens were recommended to patients (gluten-free, low-sodium, high-fiber diets, etc.), who recommended these nutritional counseling, changes patients made in their dietary habits since the diagnosis of their IMID, and their perceptions of the consequences of this change. Information on nutrition materials and services recommended to patients were also collected and a 0-to-10 rating scale was used to score patient satisfaction with the recommended information tools (0 = not at all; 10 = totally).

Patients' perception of nutrition was assessed according to two dimensions: attitude toward change in dietary habits and the reported consequences.

Statistical analysis

Our objective was to include 50 patients per disease. Eligible patients were included in the study when they started filling in the questionnaire. Only data of patients who completed the questionnaire within the study period (12 April, 2019–13 May, 2019) were analyzed. A selection of the patients included in the analyses was based on the consistency of the answers and on the time of survey completion once the target was exceeded.

Descriptive statistics were applied. Categorical variables were expressed as absolute frequency and percentage. For continuous variables, data were presented as mean (CI95%: Confident interval 95%) if normal distribution was observed and as median and interquartile range if non-normal distribution was observed. Diseases were categorized into rheumatologic diseases (RA, SA and PsA), gastro-intestinal or inflammatory bowel diseases (IBD: CD and UC) and PsO. Results are presented by disease group, overall, and by disease (when relevant). Descriptive analyses were performed using Excel® 2013. Statistical analyses were performed using R studio (v3.5.0).

Results

Study population

From April 12 to May 13, 2019, 300 patients who fulfilled the inclusion criteria and were willing to participate were included in the study; 50 patients were recruited per target disease (Fig. 1).

The demographic and disease characteristics of the study population are presented in Table 1. While mean age was generally consistent across the diseases (ranging from 44.7 years (95%CI 41.4–48.0) for patients with CD to 50.8 years (95%CI 46.5 – 55.0) for patients with PsO) some sociodemographic and clinical characteristics were different between the disease populations. The great majority of patients with rheumatologic diseases and CD were women (87% and 82%, respectively), against 58% of patients with UC and 68% with PsO. Almost half the overall population were overweight or obese with BMI also varying across diseases: the majority of patients with PsO (54%), RA (60%) and PsA (66%) were overweight or obese compared to 36% of patients with IBD.

Age at diagnosis and mean time since diagnosis varied widely across diseases. The mean duration of illness was longest for patients with PsO and they were diagnosed at a younger age than patients with IBD and rheumatic diseases which were diagnosed more recently at a more advanced age. At least four of ten patients declared having another chronic disease, ranging from 22% of patients with RA to 66% of patients with AS. In 38% of the cases, the other chronic disease reported was another IMID: PsO and AS were reported in 13 patients (10%), CD in 11 patients (8%), asthma and fibromyalgia both in 8 patients (6%), PsA in 7 patients (5%) and multiple sclerosis in 5 patients (4%). Regardless of the disease, more than three-quarters of patients reported complications since the time of their diagnosis of their IMID. Complications were different across diseases, but depression and overweight were reported by approximately four of ten and more than a quarter of all patients, respectively.

At the time of their inclusion in the study, 93% of all patients were monitored by an HCP. While at least 90% of patients with rheumatologic diseases or IBD received care from a rheumatologist or gastroenterologist, mainly at a hospital or in a clinic (73% and 84%), only 56% of patients with PsO were monitored by a dermatologist and 24% by a general practitioner, mainly in private practice (74%). Noteworthy, 22% of patients with PsO and 12% of patients with UC were not currently under the care of an HCP. Patients with PsA declared attending a hospital or clinic in 56% of the cases.

Patients' perception of their level of control of their disease varied across disease groups and within a group (Table 1). Lower level of control was observed for patients with PsA (4.2/10 95%CI 3.4-5.0), AS (4.5/10 95%CI 3.8–5.1) and PsO (4.8/10 95%CI 4.0-5.5).

Table 1. Socio-demographic and disease characteristics of the study population by disease group (N = 300)

NC, not collected; NA, not available; IMID, immune-mediated inflammatory diseases; HCP, healthcare professionals.

§ 16% of patients with psoriatic arthritis.

Variable	Rheumatic diseases (N = 150)	Gastrointestinal diseases (N = 100)	Psoriasis (N = 50)	Overall (N = 300)
Sociodemographic variables				
Age, years Mean (95%CI)	48.8 (47.0-50.6)	45.9 (43.2–48.5)	50.8 (46.5–55.0)	48.1 (46.7–49.6)
Age groups, N (%)	9 (6)	12 (12)	4 (8)	25 (8)
18–30 years	28 (19)	24 (24)	12 (24)	64 (21)
31–40 years	44 (29)	27 (27)	11 (22)	82 (28)
41–50 years	47 (31)	23 (23)	8 (16)	78 (26)
51–60 years	19 (13)	11 (11)	9 (18)	39 (13)
61–70 years	3 (2)	3 (3)	6 (12)	12 (4)
> 70 years				
Gender, N (%) Female	130 (87)	70 (70)	34 (68)	234 (78)
Socio-professional category, N (%)	75 (50)	47 (47)	21 (42)	143 (55)
Employee	33 (22)	19 (19)	16 (32)	68 (26)
Executive and senior intellectual profession	10 (7)	7 (7)	1 (2)	18 (7)
Intermediate profession	10 (7)	5 (5)	3 (6)	18 (7)
Craftsman, trader, company manager	3 (2)	7 (7)	4 (8)	14 (5)
Worker				
Body Mass Index, N (%)				
Underweight (< 18.5 kg/m ²)	10 (7)	9 (9)	3 (6)	22 (7)
Normal weight (18.5 and 25 kg/m ²)	57 (38)	55 (55)	20 (40)	132 (44)
Overweight (25 and 30 kg/m ²)	47 (31)	25 (25)	10 (20)	82 (28)
Obese (> 30 kg/m ²)	33 (22)	11 (11)	17 (34)	61 (20)
Inconsistent answer	3 (2)	0	0	3 (1)
Disease variables				

Variable	Rheumatic diseases (N = 150)	Gastrointestinal diseases (N = 100)	Psoriasis (N = 50)	Overall (N = 300)
Disease duration, years Mean (95%CI)	7.3 (5.9–8.7)	12.9 (10.8–15.0)	23.5 (19.5–27.4)	11.5 (10.2–12.8)
Age at diagnosis, years Mean (95%CI)	41.3 (39.5–43.2)	33.2 (30.7–35.7)	27.0 (22.0–32.0)	36.5 (34.9–38.1)
Comorbidities, N (%) Another IMID	68 (45)	40 (40)	22 (44)	130 (43) 49 (38)
HCP, N (%) Rheumatologist Gastroenterologist General practitioner Dermatologist Not monitored	140 (93) 4 (3) 42 (28) 12 (8)§ 2 (1)	6 (6) 90 (90) 17 (17) 6 (6) 8 (8)	2 (4) 0 (0) 12 (24) 28 (56) 11 (22)	148 (49) 94 (31) 71 (24) 46 (15) 21 (7)
Care facilities, N (%) Hospital or clinic only Private practice only Both private practice and hospital/clinic	60 (41) 41 (28) 47 (32)	54 (59) 15 (16) 23 (25)	10 (26) 22 (56) 7 (18)	124 (44) 78 (28) 77 (28)
Complications, N (%) At least one Depression Overweight Appetite disorders Articular disorders Dry eyes/mouth None	125 (83) 59 (39) 53 (35) 32 (21) NC 49 (33) 25 (17)	89 (89) 42 (42) 25 (25) 29 (29) 41 (41) NC 11 (11)	38 (76) 20 (40) 13 (26) 9 (18) 19 (38) NC 12 (24)	NA NA NA NA NA NA NA

Variable	Rheumatic diseases (N = 150)	Gastrointestinal diseases (N = 100)	Psoriasis (N = 50)	Overall (N = 300)
Perception of the patients' level of control of the disease, score	4.8 (4.4–5.3)	5.9 (5.4–6.4)	4.8 (4.0–5.5)	5.2 (4.9–5.5)
Mean (95%CI)	48 (32)	24 (24)	20 (40)	92 (31)
Poorly controlled (score < 4), N (%)	61 (41)	32 (32)	16 (32)	109 (36)
Moderately controlled (score 4–7)	41 (27)	44 (44)	14 (28)	99 (33)
Well controlled (score > 7)				

Patients with CD reported a better control of their disease (6.1/10 95%CI 5.4–6.8) (Fig. 2).

Nutritional advices

Throughout their care history, more than half of all patients (56%) were given some nutritional advice, mostly by the HCP monitoring their disease (36%) or another HCP (42%). Some patients reported having received recommendations from other patients or the Internet (25%), but very few received information from patient organizations (5%). The type of recommendations varied by the disease and the patient's BMI (Table 2). The diets recommended for patients with rheumatic diseases varied according to the disease; patients with AS were mainly advised to consume a gluten-free (32%) diet, different diets were recommended to patients with RA and PsA. Low-salt, low-calorie, low-sugar or gluten-free diets were recommended to 38%, 30%, 26% and 24% of patients with RA, respectively. Patients with PsA were advised to reduce their sugar (26%) and salt (20%) intake or eat a gluten-free (20%) diet. Patients with IBD were more frequently advised to have a low-fiber (50%), low-salt (33%) or gluten-free (32%) diet. Patients with PsO declared having received little advice on nutrition (Table 2). Reducing calorie and sugar intake was frequently advised to overweight patients (62% and 57%, respectively).

Table 2. Type of nutritional advice received by disease (N = 300)

AS: ankylosing spondylitis; RA: rheumatoid arthritis; PsA: psoriatic arthritis; CD: Crohn's disease; UC: ulcerative colitis

	Rheumatic diseases			Gastrointestinal diseases		Psoriasis (N = 50)	Overall (N = 300)
	AS	RA	PsA	CD	UC	N (%)	N (%)
	(N = 50)	(N = 50)	(N = 50)	(N = 50)	(N = 50)		
	N (%)	N (%)	N (%)	N (%)	N (%)		
Gluten-free diet	16 (32)	12 (24)	10 (20)	16 (32)	16 (32)	4 (8)	74 (25)
Low-salt diet	4 (8)	19 (38)	10 (20)	17 (34)	16 (32)	2 (4)	68 (23)
Low-fiber diet	4 (8)	5 (10)	3 (6)	29 (58)	21 (42)	0 (0)	62 (21)
Low-sugar diet	4 (8)	13 (26)	13 (26)	10 (20)	12 (24)	8 (16)	60 (20)
High-fiber diet	8 (16)	11 (22)	6 (12)	2 (4)	15 (30)	6 (12)	48 (16)
Low-calorie diet	3 (6)	15 (30)	8 (16)	7 (14)	8 (16)	1 (2)	42 (14)
High-protein diet	4 (8)	8 (16)	4 (8)	12 (24)	11 (22)	2 (4)	41 (14)
Fasting diet	3 (6)	4 (8)	5 (10)	9 (18)	13 (26)	5 (10)	39 (13)
No recommendation	29 (58)	17 (34)	27 (54)	10 (20)	15 (30)	35 (70)	133 (44)

Change in dietary habits

Since diagnosis, 34%, 70% and 20% of the total patients with rheumatic diseases, IBD, and PsO stated they changed their eating habits, respectively (Table 3). Regardless of the disease, this change was initiated more frequently by the patient than by their HCP (69% vs 31% overall). Of the 169 respondents who did not change their eating habits after initial diagnosis, 69% did not receive nutritional advice from their HCP. Of the approximately one-third of patients with rheumatic diseases and IBD who received nutritional advice from their HCPs, 35% and 63% followed this advice. Only 8 of 50 patients with PsO were recommended specific diets and 2 of them applied them (Table 3).

Table 3. Change in eating habits since diagnosis, by disease group (N = 300)

HCP: healthcare professionals

Variable	Rheumatic diseases (N = 150)	Gastrointestinal diseases (N = 100)	Psoriasis (N = 50)	Overall (N = 300)
Change, N (%)	51 (34)	70 (70)	10 (20)	131 (44)
Yes	99 (66)	30 (30)	40 (80)	169 (56)
No				
Person who recommended change, N (%)	33 (65)	49 (70)	8 (80)	90 (69)
Patient his/herself	18 (35)	21 (30)	2 (20)	41 (31)
HCP				
Reason for no change, N (%)	34 (34)	12 (40)	6 (15)	52 (31)
Patient decision despite HCP advice, %	65 (66)	18 (60)	34 (85)	117 (69)
No advice from HCP, %				

Impact of diet change

Two-thirds of the patients (66%) who had modified their diet experienced a change as a consequence. Even though positive consequences including weight loss, better physical fitness and improved mental health were observed by 27%, 27% and 13% of patients, some negative consequences were reported such as increased fatigue (21%), disturbed sleep (15%) and difficulty carrying out normal physical activities (14%). The perceived consequences of the change in diet varied across the diseases. Patients with rheumatic diseases reported weight loss (33%) and better physical fitness (30%) but 24% of those with RA also mentioned increased fatigue. While 43% of patients with UC declared having better physical fitness and few negative effects (13% of all UC cases), patients with CD mentioned increased tiredness (43%), disturbed sleep (28%) and difficulty carrying out normal physical activities (28%). Noteworthy, one of five patients with CD reported feeling their nutritional intake was insufficient. Patients with PsO reported, beyond weight loss (50%) and better physical activity (30%), an improved mental health (30%) and reduced stress (20%), but no negative consequences. A non-negligible proportion of all patients stated they did not feel the change in their diet produced any consequences (25–38% of patients) (Fig. 3).

Nutrition services and informational materials

Overall, 24% of the patients were offered informational materials or services on nutrition. This varied depending on the diseases: 16% with rheumatic diseases (8% for PsA, 16% for AS and 24% for RA patients), 40% of patients with IBD, and 10% with PsO. They were mainly offered brochures (29%) or referral to nutritionist services (28%). Overall, patients were slightly dissatisfied with the information and/or services provided (overall median score = 4.5/10, with 10 = totally satisfied; Q1-Q3:2.5-6.0).

Median satisfaction scores varied across diseases from 2.5 (Q1-Q3:2.5–5.5) for AS to 4.8 for CD (Q1-Q3:3.1-6.0) to UC (Q1-Q3:2.0-6.4) patients. Patients who had changed their eating habits as per the advice of HCP tended to be more satisfied with nutrition services and informational materials (mean score = 5.8 (95%: 4.6–6.9)) than those who self-imposed their diet (mean score = 3.8 (95%: 2.8–4.8)).

Discussion

A combination of genetic susceptibility and environmental exposure are suspected to be the cause of IMID [7, 32]. Among the environmental factors, nutrition may play a role in IMID, both through the intestinal microbiota and dietary intake leading to overweight [8]. However, the role of nutrition in disease management from the patients' perspectives has rarely been described. It is now widely agreed that patients' involvement in therapeutic care, both pharmacological and non-drug interventions, improves health outcomes. Patients' active participation and involvement in decisions on their own care process and health is encouraged [33]. In the context of dietary therapy, patients' active involvement in decision making and adherence to treatment are key to observing benefits [34]. In fact, the health benefits of dietary treatment is more closely related to the degree of the individual's adherence to treatment than the type of diet administered [35]. To adequately involve the patient in his/her own care, it is important to acknowledge his/her perceptions of the proposed therapy.

To our knowledge, this is the first observational study to collect real-life data about patients' attitudes and perceptions of nutrition and its impact on their disease in different types of IMIDs, including rheumatic diseases and PsO. Our findings show that patients consider nutrition an important aspect of their disease management. Almost half the study participants (44%) changed their eating habits, mainly patients with IBD. Of these patients, more than two-thirds made the change on their own initiative. However, we don't know if the dietary adjustments made by the patients were aligned with the advices given by HCPs. Among the patients who did not change their eating habits, 69% stated they did not receive nutritional advice from their HCP. The results also suggest patients positively perceived the impact of nutrition on their symptoms, with 74% reporting positive consequences; however, 60% of patients reported some negative consequences of their dietary changes, with consequences varying by disease. The ten patients with PsO who made dietary changes only experienced positive consequences including reduction of stress and improved mental health which is particularly beneficial to these patients as they are commonly affected by stress and anxiety. Patients with rheumatic diseases and UC reported positive impacts such as weight loss and better physical fitness, but also increased fatigue. Even if some of them reported weight loss and better physical fitness, patients with CD tended to report rather negative effects such as increased fatigue, disturbed sleep and difficulty carrying out normal physical activities.

Half the patients who felt their disease was well controlled (perception score > 7) had changed their eating habits, against 43% and 38% of patients who felt their disease was moderately and poorly controlled, respectively. Only one-quarter of the patients who received nutrition services or informational materials in the form of brochures or access to a nutritionist were moderately satisfied with those tools. The majority of those patients reported with IBD. Regardless whether patients have already received

dietary advice, half of them voluntarily mentioned they had additional expectations about nutrition-related information, mainly practical, general, or disease-specific advice, to be given by nutritionists or clinicians. This information gap led them to independently research and implement dietary interventions from other sources such as the internet without professional monitoring. This may produce sub-optimal disease management, worsen the disease, create deficiencies, facilitate the development of other diseases, and may even be dangerous in the case of restrictive or popular fad diets. Additionally, some diets are associated with a non-negligible burden for the patients which can impair their quality of life and lead to the discontinuation of therapy.

As seen above, the potential negative side effects of diets combined with the high proportion of patients who are self-initiating dietary changes strongly suggests the importance of carefully-advised nutritional intervention and monitoring by professionals: the HCP in charge of the patient and nutrition specialists. Effective communication and collaboration between patients and HCPs is known to increase patient adherence [36] and helps HCPs to understand patients' difficulties, perspectives and perceptions while informing their jointly-planned treatment course. While patients' organizations are very active in nutrition in some diseases, especially IBD, it's surprising that very few patients from our survey declared having received dietary recommendations from them. There is, thus, still room for increasing patient organizations' involvement in promoting nutritional interventions in collaboration with HCP.

The study population was recruited from a patient social platform which has several benefits. Firstly, patients in social networks are more willing to share experience and feel freer to express themselves anonymously and confidentially without their HCP's involvement (which has been shown to limit the social desirability bias [37]). Secondly, those networks provide an opportunity to collect patient-reported outcomes that complement and add value to clinical data while empowering patients and putting them at the center of their own care. The use of such patients' platforms; however, limits the researcher's ability to include individuals who do not have access to the online tool and thus may lead to a potential recruitment bias [38].

In our study, all data were reported by the patients themselves through closed-ended but also open-ended questions, which allowed for collection of patient opinions, perceptions and expectations; however, clinical data provided by the patient was not confirmed by clinicians, thus introducing self-reporting bias including recall bias. Furthermore, as is common in self-administered questionnaires, only patients having the capacity to answer have participated.

Conclusion

Even if differences exist across diseases, a similar behavior towards a positive perception of the importance of nutrition and its potential role in symptoms management was reported by most of the IMID patients. While the role played by diet in inflammatory process is more and more considered and scientific and medical data start emerging for some diseases, robust data coming from well-designed clinical trials are still insufficient to allow evidence-based nutritional recommendations and systematic

integration into the normal comprehensive care pathway [22]. However, as highlighted in our study, there is a great need and demand from patients to receive dietary advices from their HCP. This suggests that developing therapeutic education tools on nutrition for people affected by IMID would provide useful information to the patient and his/her family and relatives even if it may not completely meet patients' expectations for nutrition education. It will however encourage effective communication between HCP and patients with IMID which a key component of patients care. Patients' organizations involvement in dietary recommendations as a therapeutic measure in IMID management may also accentuate patient satisfaction.

List Of Abbreviations

AS: Ankylosing spondylitis; BMI: Body mass index; CD: Crohn's disease; CI95%: Confident interval 95%; HCP: Healthcare professional; IBD: Inflammatory Bowel Disease; IMID: Immune-mediated inflammatory diseases; PsA: Psoriatic arthritis; PsO: Psoriasis; RA: Rheumatoid Arthritis; UC: Ulcerative colitis

Declarations

Ethics approval and consent to participate

The procedures followed for this study were in accordance with the French Law 78–17 of 6 January 1978 and its later amendments and the General Data Protection Regulation.

The study was conducted in accordance with Good Epidemiological Practices.

Our satisfaction survey (Market Research) is not qualified as a research involving the human person and does not fall within the scope of the article L1121-1

(https://www.legifrance.gouv.fr/codes/article_lc/LEGIARTI000034696952/), modified by the decree n°2017-884 (https://www.legifrance.gouv.fr/jorf/article_jo/JORFARTI000034634225).

Thus, the satisfaction survey is apart from any submission to a French ethic committee (Comité de Protection des Personnes, CPP) and to the French health authority (ANSM), as mentioned by the article L1123-8 (https://www.legifrance.gouv.fr/codes/article_lc/LEGIARTI000025457560/2012-03-07).

Before their inclusion in the study, all patients were informed about the aim, method and duration of the study and have consented expressly and specifically to the collection, handling and storage of their personal and health data. All participants were free to withdraw from the study at any time without notice or reason.

Consent for publication

Not applicable.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests

TP has received consulting/conference fee from AbbVie, Biogen, BMS, Chugai, Gilead, Fresenius Kabi, Janssen, Lilly, Medac, MSD, Nordic Pharma, Novartis, Pfizer, Roche, Sandoz, Sanofi, UCB.

HS has received consulting/conference fee from Enterome, Ferring, Fresenius, Amgen, MSD, BMS, Takeda, Biocodex, Pfizer, Sanofi, Janssen, Astellas, Gilead, Danone, Roche, BiomX, Adare, Eligo. Co-founder of Exceliom Bioscience.

BH has received consulting/conference fee from Celgene, Leo Pharma, Lilly and Fresenius Kabi.

GP and MB are Fresenius Kabi France employees.

EP and DT are Carecity employees.

Funding

The Study was funded by Fresenius Kabi France.

Authors' contributions

EP and DT conceptualised and designed the study, acquired, cleaned, managed and analysed the data, and drafted and revised the manuscript. BH, HS, TP, GP and MB conceptualised and designed the study, interpreted the data, and drafted and revised the manuscript. All authors gave final approval of the version to be published and agree to be accountable for all aspects of the work.

Acknowledgements

The authors would like to thank the patients from the Carecity Communities who participated in this survey.

References

1. American Autoimmune Related Diseases Association. Autoimmune diseases list. Available from: <https://www.aarda.org/diseaselist/> [Accessed October 2019]
2. McCain J. The Disease Burden of the Most Common Autoimmune Diseases. *Managed Care* 2016; Jul;25(7):28-32. Available from: <https://www.managedcaremag.com/archives/2016/7/disease-burden-most-common-autoimmune-diseases> [Accessed October 2019]
3. Olesińska M and Saletra A. Quality of life in systemic lupus erythematosus and its measurement. *Reumatologia*. 2018; 56(1): 45–54. Available from: doi:10.5114/reum.2018.74750.

4. Greenfield J, Hudson M, Vinet E, Fortin PR, Bykerk V, Pineau CA, et al. Canadian Scleroderma Research Group and Canadian Inflammatory Myopathy Study Group. [A comparison of health-related quality of life \(HRQoL\) across four systemic autoimmune rheumatic diseases \(SARDs\)](#). *PLoS One*. 2017 Dec 19;12(12):e0189840. Available from: doi:10.1371/journal.pone.0189840.
5. Makredes M, Robinson D Jr, Bala M, Kimball AB. The burden of autoimmune disease: a comparison of prevalence ratios in patients with psoriatic arthritis and psoriasis. *J Am Acad Dermatol*. 2009 Sep;61(3):405-10. Available from: doi:10.1016/j.jaad.2009.02.015.
6. Wang L, Wang FS, Gershwin ME. Human autoimmune diseases: a comprehensive update. *J Intern Med*. 2015;278:369-395. Available from: doi:10.1111/joim.12395.
7. Anaya JM. The autoimmune tautology. *Arthritis Res Ther*. 2010;12(6):147. Available from: doi:10.1186/ar3175.
8. Anaya JM, Ramirez-Santana C, Alzate MA, Molano-Gonzalez N, Rojas-Villarraga A. The Autoimmune Ecology. *Front Immunol*. 2016; Apr 26; 7:139. Available from: doi:10.3389/fimmu.2016.00139. eCollection 2016.
9. Brodin P, Jojic V, Gao T, Bhattacharya S, Angel CJ, Furman D, et al. Variation in the human immune system is largely driven by non-heritable influences. *Cell*. 2015; 160(1–2):37–47. Available from: doi:10.1016/j.cell.2014.12.020.
10. Lerner A, Jeremias P, Matthias T. The world incidence and prevalence of autoimmune diseases is increasing. *International Journal of Celiac Disease*. 2015;3(4):151-155. Available from: doi:10.12691/ijcd-3-4-8.
11. Schmidt CW. Questions persist: environmental factors in autoimmune disease. *Environ Health Perspect*. 2011 Jun;119(6):A249-53. Available from: doi: 10.1289/ehp.119-a248.
12. Thorburn AN, Macia L, Mackay CR. Diet, metabolites, and "western-lifestyle" inflammatory diseases. *Immunity*. 2014 Jun 19;40(6):833-42. Available from: doi:10.1016/j.immuni.2014.05.014.
13. Vieira SM, Pagovich OE, Kriegel MA. Diet, microbiota and autoimmune diseases. *Lupus*. 2014 May;23(6):518-26. Available from: doi:10.1177/0961203313501401.
14. Choi IY, Lee C, Longo VD. Nutrition and fasting mimicking diets in the prevention and treatment of autoimmune diseases and immunosenescence. *Mol Cell Endocrinol*. 2017 Nov 5;455:4-12. Available from: doi:10.1016/j.mce.2017.01.042.
15. Masuko A Potential Benefit of "Balanced Diet" for Rheumatoid Arthritis. *Front Med*. 2018; 5: 141. Available from: doi:10.3389/fmed.2018.00141.
16. European Parliament. Autoimmune Diseases – Modern Diseases: report. 2017. Available from: [https://www.europarl.europa.eu/cmsdata/133620/ENVI%202017-09%20WS%20Autoimmune%20diseases%20%20PE%20614.174%20\(Publication\).pdf](https://www.europarl.europa.eu/cmsdata/133620/ENVI%202017-09%20WS%20Autoimmune%20diseases%20%20PE%20614.174%20(Publication).pdf) [Accessed October 2019].
17. Scudellari, M. Cleaning up the hygiene hypothesis. *Proc Natl Acad Sci*. 2017 Feb; 114(7): 1433–1436. Available from: doi:10.1073/pnas.1700688114.

18. Sharpton T, Lyalina S, Luong J, Pham J, Deal EM, Armour C, et al. Development of inflammatory bowel disease is linked to a longitudinal restructuring of the gut metagenome in mice. *mSystems*. 2017;2 (5) e00036–e00017. Available from: doi: 10.1128/mSystems.00036-17.
19. Knoll RL, Forslund K, Kultima JR, Meyer CU, Kullmer U, Sunagawa S, et al. Gut microbiota differs between children with inflammatory bowel disease and healthy siblings in taxonomic and functional composition: a metagenomic analysis. *Am J Physiol-Gastrointest Liver Physiol*. 2017;312:G327–G339. Available from: doi:10.1152/ajpgi.00293.2016.
20. Liu X, Zeng B, Zhang J, Li W, Mou F, Wang H, et al. Role of the gut microbiome in modulating arthritis progression in mice. *Sci Rep*. 2016;6:30594. Available from: doi:10.1038/srep30594.
21. Chen J, Wright K, Davis JM, Jeraldo P, Marietta EV, Murray J, et al. An expansion of rare lineage intestinal microbes characterizes rheumatoid arthritis. *Genome Med*. 2016;8:43. Available from: doi:10.1186/s13073-016-0299-7.
22. Lee D., Albenberg L., Compher C., Baldassano R., Piccoli D., Lewis JD, et al. Diet in the Pathogenesis and Treatment of Inflammatory Bowel Diseases. *Gastroenterology*. 2015 May; 148(6): 1087–1106. Available from: doi:10.1053/j.gastro.2015.01.007.
23. Hou JK, Abraham B, El-Serag H. Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. *Am J Gastroenterol*. 2011 Apr;106(4):563-73. Available from: doi:10.1038/ajg.2011.44.
24. Gioia C, Lucchino B, Tarsitano MG, Iannuccelli C, Di Franco M. Dietary Habits and Nutrition in Rheumatoid Arthritis: Can Diet Influence Disease Development and Clinical Manifestations?. *Nutrients*. 2020;12(5):1456. Published 2020 May 18. Available from: doi:10.3390/nu12051456.
25. Schwarz S, Leweling H. Multiple sclerosis and nutrition. *Mult Scler*. 2005 Feb;11(1):24-32. Available from: doi: 10.1191/1352458505ms11190a.
26. Brown AC, Rampertab SD, Mullin GE. Existing dietary guidelines for Crohn's disease and ulcerative colitis. *Expert Rev Gastroenterol Hepatol*. 2011 Jun;5(3):411-25. Available from: doi:10.1586/egh.11.29.
27. Durchschein F, Petritsch W, Hammer HF. Diet therapy for inflammatory bowel diseases: The established and the new. *World J Gastroenterol*. 2016 Feb 21;22(7):2179-94. doi: 10.3748/wjg.v22.i7.2179.
28. Vitetta L, Coulson S, Schloss, Beck, Allen, Sali A. (2012). Dietary recommendations for patients with rheumatoid arthritis: a review. *Nutrition and Dietary Supplements*. *Nutrition and Dietary Supplements*. 4. 1-15. June 2012. <https://doi.org/10.2147/NDS.S6922>
29. Hansen T, Duerksen DR. Enteral Nutrition in the Management of Pediatric and Adult Crohn's Disease. *Nutrients*. 2018 Apr 26;10(5). pii: E537. doi: 10.3390/nu10050537.
30. Comeche JM, Caballero P, Gutierrez-Hervas A, et al. Enteral Nutrition in Patients with Inflammatory Bowel Disease. Systematic Review, Meta-Analysis, and Meta-Regression. *Nutrients*. 2019;11(11):2657. Published 2019 Nov 4. doi:10.3390/nu11112657

31. M. Ruemmele, G. Veres, K.L. Kolho, A. Griffiths, A. Levine, J.C. Escher, J. Amil Dias, A. Barabino, C.P. Braegger, J. Bronsky, S. Buderus, J. Martín-de-Carpi, L. De Ridder, U.L. Fagerberg, J.P. Hugot, J. Kierkus, S. Kolacek, S. Koletzko, P. Lionetti, E. Miele, V.M. Navas López, A. Paerregaard, R.K. Russell, D.E. Serban, R. Shaoul, P. Van Rheenen, G. Veereman, B. Weiss, D. Wilson, A. Dignass, A. Eliakim, H. Winter, D. Turner. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease, *Journal of Crohn's and Colitis*. Volume 8, Issue 10, 2014, Pages 1179-1207, ISSN 1873-9946, <https://doi.org/10.1016/j.crohns.2014.04.005>.
32. Cárdenas-Roldán J, Rojas-Villarraga A, Anaya JM. How do autoimmune diseases cluster in families? A systematic review and meta-analysis. *BMC Med* 2013; Mar 18;11:73. doi: 10.1186/1741-7015-11-73.
33. Thompson AG. The meaning of patient involvement and participation in health care consultations: a taxonomy. *Soc Sci Med* 2007;64(6):1297–310. doi: 10.1016/j.socscimed.2006.11.002.
34. Sofi F, Cesari F, Abbate R, Gensini GF, Casini A. Adherence to Mediterranean diet and health status: meta-analysis. *British Medical Journal* 2008;11: 337–344. doi: 10.1136/bmj.a1344
35. Vaillancourt H, Légaré F, Lapointe A, Deschênes SM, Desroches S. Assessing patients' involvement in decision making during the nutritional consultation with a dietitian. *Health Expect* 2014 Aug;17(4):545-54. doi: 10.1111/j.1369-7625.2012.00783.x.
36. Cohen SM. Concept analysis of adherence in the context of cardiovascular risk reduction. *Nursing Forum* 2009;44:25–36. doi: 10.1111/j.1744-6198.2009.00124.x.
37. Wicks P, Stamford J, Grootenhuis MA, Haverman L, Ahmed S. Innovations in e-health. *Qual Life Res* 2014;23:195–203. doi: 10.1007/s11136-013-0458-x.
38. Ravoire S, Lang M, Perrin E. Advantages and limitations of online communities of patients for research on health products. *Therapie*. 2017;72:135–43. doi: 10.1016/j.therap.2016.11.058.

Figures




Figure 1

Flowchart of study participants. AD, autoimmune disease




Figure 2

Mean scores of patients' perception of the level of control of their disease (N=300). Bars above and below the histogram indicate the upper and lower bounds of the CI95%. Patients perceptions of their level of control over their disease was determined through an 11-item scale (0=not at all controlled; 10=perfectly controlled). AS, ankylosing spondylitis; RA, rheumatoid arthritis; PsA, psoriatic arthritis; CD, Crohn's disease; UC, ulcerative colitis; PsO, psoriasis.




Figure 3

Perceived impact of change in dietary habits by disease group (N=131, 239 answers). AS: ankylosing spondylitis; RA: rheumatoid arthritis; PsA: psoriatic arthritis; CD: Crohn's disease; UC: ulcerative colitis.